Authors:
Becker, S
Fisher, A
Flexner, C
Gerber, JG
Haubrich, R
Kashuba, ADM
Luber, AD
Piscitelli, SC
Citation: S. Becker et al., Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio:Call for consensus, J ACQ IMM D, 27(2), 2001, pp. 210-211
Authors:
Eron, JJ
Haubrich, R
Lang, W
Pagano, G
Millard, J
Wolfram, J
Snowden, W
Pedneault, L
Tisdale, M
Citation: Jj. Eron et al., A phase II trial of dual protease inhibitor therapy: Amprenavir in combination with indinavir, nelfinavir, or saquinavir, J ACQ IMM D, 26(5), 2001, pp. 458-461
Citation: L. Demeter et R. Haubrich, Phenotypic and genotypic resistance assays: Methodology, reliability, and interpretations, J ACQ IMM D, 26, 2001, pp. S3-S9
Citation: R. Haubrich et L. Demeter, Clinical utility of resistance testing: Retrospective and prospective datasupporting use and current recommendations, J ACQ IMM D, 26, 2001, pp. S51-S59
Authors:
Schooley, RT
Clumeck, N
Haubrich, R
Thompson, M
Danner, SA
van Der Ende, ME
Sereni, D
Antunes, F
Blake, D
Myers, RE
Tisdale, M
Millard, J
Mustafa, N
Nacci, P
Citation: Rt. Schooley et al., A dose-ranging study to evaluate the antiretroviral activity and safety ofamprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience, ANTIVIR TH, 6(2), 2001, pp. 89-96
Authors:
McMahon, D
Lederman, M
Haas, DW
Haubrich, R
Stanford, J
Cooney, E
Horton, J
Kelleher, D
Ross, L
Cutrell, A
Lee, D
Spreen, W
Mellors, JW
Citation: D. Mcmahon et al., Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults, ANTIVIR TH, 6(2), 2001, pp. 105-114
Authors:
Kemper, CA
Witt, MD
Keiser, PH
Dube, MP
Forthal, DN
Leibowitz, M
Smith, DS
Rigby, A
Hellmann, NS
Lie, YS
Leedom, J
Richman, D
McCutchan, JA
Haubrich, R
Citation: Ca. Kemper et al., Sequencing of protease inhibitor therapy: insights from an analysis of HIVphenotypic resistance in patients failing protease inhibitors, AIDS, 15(5), 2001, pp. 609-615
Authors:
Sadler, BM
Gillotin, C
Lou, Y
Eron, JJ
Lang, W
Haubrich, R
Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir, ANTIM AG CH, 45(12), 2001, pp. 3663-3668
Authors:
Katzenstein, DA
Hughes, M
Albrecht, M
Hammer, S
Para, M
Murphy, R
Valdez, H
Haubrich, R
Liou, S
Citation: Da. Katzenstein et al., Virologic and CD4(+) cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection, AIDS RES H, 16(11), 2000, pp. 1031-1037
Authors:
Sha, BE
Johnson, VA
Kendall, MA
Haubrich, R
Nokta, M
Lamb, K
Zackin, RA
Nail, CD
Currier, JS
Citation: Be. Sha et al., Absence of virological changes after acute febrile illnesses in two patients with undetectable pre-illness plasma HIV-1-RNA levels, AIDS, 14(6), 2000, pp. 746-748
Authors:
Lederman, MM
McKinnis, R
Kelleher, D
Cutrell, A
Mellors, J
Neisler, M
Cooney, E
Haas, DW
Haubrich, R
Stanford, J
Horton, J
Landay, A
Spreen, W
Citation: Mm. Lederman et al., Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase, AIDS, 14(17), 2000, pp. 2635-2642
Authors:
Fletcher, CV
Acosta, EP
Cheng, HL
Haubrich, R
Fischl, M
Raasch, R
Mills, C
Hu, XJ
Katzenstein, D
Remmel, RP
Gulick, RM
Citation: Cv. Fletcher et al., Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884, AIDS, 14(16), 2000, pp. 2495-2501
Authors:
Gulick, RM
Hu, XJ
Fiscus, SA
Fletcher, CV
Haubrich, R
Cheng, HL
Acosta, E
Lagakos, SW
Swanstrom, R
Freimuth, W
Snyder, S
Mills, C
Fischl, M
Pettinelli, C
Katzenstein, D
Citation: Rm. Gulick et al., Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359, J INFEC DIS, 182(5), 2000, pp. 1375-1384
Authors:
Gunthard, HF
Wong, JK
Spina, CA
Ignacio, G
Kwok, S
Christopherson, C
Hwang, J
Haubrich, R
Havlir, D
Richman, DD
Citation: Hf. Gunthard et al., Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy, J INFEC DIS, 181(2), 2000, pp. 522-531
Authors:
Revicki, DA
Swartz, C
Wu, AW
Haubrich, R
Collier, AC
Citation: Da. Revicki et al., Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm(3), ANTIVIR TH, 4(1), 1999, pp. 35-44
Authors:
Haubrich, R
Thompson, M
Schooley, R
Lang, W
Stein, A
Sereni, D
van der Ende, ME
Antunes, F
Richman, D
Pagano, G
Kahl, L
Fetter, A
Brown, DJ
Clumeck, N
Citation: R. Haubrich et al., A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviralexperience, AIDS, 13(17), 1999, pp. 2411-2420
Citation: R. Haubrich et D. Richman, Nevirapine, didanosine, and zidovudine for patients with HIV: The INCAS trial, J AM MED A, 281(2), 1999, pp. 130-131